Guastalla JP - Search Results

1

Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials.

Bachelot T, Ray-Coquard I, Catimel G, Ardiet C, Guastalla JP, Dumortier A, Chauvin F, Droz JP, Philip T, Clavel M. Bachelot T, et al. Among authors: guastalla jp. Ann Oncol. 2000 Feb;11(2):151-6. doi: 10.1023/a:1008368319526. Ann Oncol. 2000. PMID: 10761748 Free article.

2

A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study group.

Ray-Coquard I, Dussart S, Goillot C, Mayeur D, Debourdeau P, Ghesquieres H, Bachelot T, Le Cesne A, Anglaret B, Agostini C, Guastalla JP, Lancry L, Biron P, Desseigne F, Blay JY. Ray-Coquard I, et al. Among authors: guastalla jp. Ann Oncol. 2009 Jun;20(6):1105-12. doi: 10.1093/annonc/mdn750. Epub 2009 Jan 27. Ann Oncol. 2009. PMID: 19174452 Free article. Clinical Trial.

3

A phase I antiemetic study of MDL 73,147EF, a novel 5-hydroxytryptamine antagonist in cancer patients receiving emetogenic chemotherapy.

Merrouche Y, Catimel G, Rebattu P, Dumortier A, Guastalla JP, O'Grady P, Clavel M. Merrouche Y, et al. Among authors: guastalla jp. Ann Oncol. 1994 Jul;5(6):549-51. doi: 10.1093/oxfordjournals.annonc.a058911. Ann Oncol. 1994. PMID: 7918128 Free article. Clinical Trial.

4

FAC (fluorouracil, doxorubicin, cyclophosphamide) as second line chemotherapy in patients with metastatic breast cancer progressing under FEC (fluorouracil, epirubicin, cyclophosphamide) chemotherapy.

Catimel G, Chauvin F, Guastalla JP, Rebattu P, Biron P, Clável M. Catimel G, et al. Among authors: guastalla jp. Ann Oncol. 1994 Jan;5(1):95-7. doi: 10.1093/oxfordjournals.annonc.a058707. Ann Oncol. 1994. PMID: 8172802 Free article.

5

Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.

Catimel G, Chabot GG, Guastalla JP, Dumortier A, Cote C, Engel C, Gouyette A, Mathieu-Boué A, Mahjoubi M, Clavel M. Catimel G, et al. Among authors: guastalla jp. Ann Oncol. 1995 Feb;6(2):133-40. doi: 10.1093/oxfordjournals.annonc.a059108. Ann Oncol. 1995. PMID: 7786821 Free article. Clinical Trial.

6

Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer.

Carrabin N, Mithieux F, Meeus P, Trédan O, Guastalla JP, Bachelot T, Labidi SI, Treilleux I, Rivoire M, Ray-Coquard I. Carrabin N, et al. Among authors: guastalla jp. Bull Cancer. 2010 Apr;97(4):E23-32. doi: 10.1684/bdc.2010.1063. Bull Cancer. 2010. PMID: 20202920 Free article.

7

The histone deacetylase inhibitor panobinostat is active in patients with advanced pretreated ovarian sex-cord tumors.

Cassier PA, Floquet A, Penel N, Derbel O, Bui N'guyen B, Guastalla JP, Pissaloux D, Treilleux I, Saba CE, Blay JY, Ray-Coquard I. Cassier PA, et al. Among authors: guastalla jp. Ann Oncol. 2014 May;25(5):1074-5. doi: 10.1093/annonc/mdu045. Epub 2014 Mar 20. Ann Oncol. 2014. PMID: 24651409 Free article. No abstract available.

8

Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.

Catimel G, Spielmann M, Dieras V, Kayitalire L, Pouillart P, Guastalla JP, Soler-Michel P, Graffand N, Garet F, Dumortier A, Pellae-Cosset B, Chazard M. Catimel G, et al. Among authors: guastalla jp. Semin Oncol. 1996 Feb;23(1 Suppl 1):24-7. Semin Oncol. 1996. PMID: 8629032 Clinical Trial.

9

Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.

Catimel G, Spielmann M, Dieras V, Tubiana-Hulin M, Bonneterre J, Pouillart P, Kayitalire L, Guastalla JP, Graffand N, Garet F, Dumortier A, Pellae-Cosset B. Catimel G, et al. Among authors: guastalla jp. Semin Oncol. 1997 Feb;24(1 Suppl 3):S8-12. Semin Oncol. 1997. PMID: 9071333 Clinical Trial.

10

Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.

Ray-Coquard I, Biron P, Bachelot T, Guastalla JP, Catimel G, Merrouche Y, Droz JP, Chauvin F, Blay JY. Ray-Coquard I, et al. Among authors: guastalla jp. Cancer. 1998 Jan 1;82(1):134-40. Cancer. 1998. PMID: 9428489

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

166 results

Search Page